What is Hackers' Pub?

Hackers' Pub is a place for software engineers to share their knowledge and experience with each other. It's also an ActivityPub-enabled social network, so you can follow your favorite hackers in the fediverse and get their latest posts in your feed.

0
0
0
0
0
0
0
0

AI isn't replacing new software engineers, but it is hurting new software engineers.

What do I mean?

A lot of the AI tools do an excellent job of specific kinds of task replacement, the kinds of tasks that you'd often given to a new software engineer.

Sure, some businesses out there are able to delay hiring new software engineers. But that's not what's hurt them.

1/4

0
0
0
0
0
0
0
0
0

SQL でカラムのデフォルト値を設定可能にしたい場合は、デフォルト値のレコードを用意してカラムに NULL が来たらトリガでデフォルト値レコードを見て設定するようにするのがいいのかな

0
0
0
0
0
0
0
0
0
0

Solving problems begins with humble doubt.

You demonstrate this doubt by asking good questions.

- How do we know this needs solving?
- How will we know when it's solved?
- Assuming we can come up with multiple hypotheses, how should we evaluate each one?
- What can we do to break the problem down in smaller parts?
- What's the shortest path in time to a solution?
- Why would we want to not try the shortest path?
- How can we share the conclusions in the most straightforward manner?

1/2

0

Umm, this is big COVID prevention news. Nobody tell RFK Jr.

Original bsky thread at link below.

“THIS IS HUGE! Researchers at Stanford University have developed a dual-antibody treatment that remains effective against ALL SARS-CoV-2 variants by targeting a less-mutable part of the virus. This breakthrough could lead to longer-lasting therapies that OUTPACE viral evolution.

The study has been published in Science. YES, it is PEER-REVIEWED. science.org/doi/10.1126/scitra

🧵 bsky.app/profile/sailorrooscou

Abstract
The ongoing emergence of severe acute respiratory syndrome coronavirus (SARS-CoV-2) variants of concern that reduce the effectiveness of antibody therapeutics necessitates development of next-generation antibody modalities that are resilient to viral evolution. Here, we characterized amino-terminal domain (NTD) - and receptor binding domain (RBD)-specific monoclonal antibodies previously
isolated from COVID-19 convalescent donors for their activity against emergent
SARS-CoV-2 VOCs.
Among these, NTD-specific antibody C1596
displayed the greatest breadth of binding to VOCs, with cryo-electron microscopy structural analysis revealing recognition of a distinct NTD epitope outside of the site i antigenic supersite. Given C1596's
favorable binding profile, we designed a series of bispecific antibodies (bsAbs), termed CoV2-biRNs, that featured both NTD & RBD specificities.
Two of the C1596-inclusive bsAbs, CoV2-biRN5 and CoV2-biRN7, retained potent in vitro neutralization activity against all Omicron variants tested, including XBB.1.5, BA.2.86, and JN.1, contrasting the diminished potency of parental antibodies delivered as monotherapies or as a cocktail. Furthermore, prophylactic delivery of CoV2-biRN5 reduced viral load within the lungs of K18-hACE2 mice after challenge with SARS-CoV-2 XBB.1.5. In conclusion, NTD-RBD bsAbs offer promising potential for the design of resilient, next-generation antibody therapeutics against SARS-CoV-2 VOCs.Diagram showing NTD Antibody + RBD Antibody leading to a combination labeled CoV2-biRNMore realistic diagram rather than the previous geometric one, showing NTD and RBD before and after the new approach has attached itself.
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0